|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003595,
umls-concept:C0015695,
umls-concept:C0020474,
umls-concept:C0020557,
umls-concept:C0030190,
umls-concept:C0032105,
umls-concept:C0439849,
umls-concept:C0441889,
umls-concept:C0445223,
umls-concept:C1314939,
umls-concept:C1552599,
umls-concept:C1704787
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-8-4
|
|
pubmed:abstractText |
Familial combined hyperlipidemia (FCHL) is a genetic form of dyslipidemia, which is characterized by an increased cardiovascular risk. The current study was conducted to investigate the relation of endothelial, inflammatory and fibrinolysis markers with the presence of hypertriglyceridemia and fatty liver in FCHL, in order to advance insight in their contribution to the cardiovascular risk profile.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0049-3848
|
|
pubmed:author |
pubmed-author:BekersOttoO,
pubmed-author:Bilderbeek-BeckersMonique A LMA,
pubmed-author:BrouwersMartijn C G JMC,
pubmed-author:Govers-RiemslagJoseJ,
pubmed-author:SchalkwijkCasper GCG,
pubmed-author:StehouwerCoen D ACD,
pubmed-author:Ten CateHugoH,
pubmed-author:Ten OeverJaapJ,
pubmed-author:de BruinTjerk W ATW,
pubmed-author:van Dieijen-VisserMarja PMP,
pubmed-author:van GreevenbroekMarleen M JMM,
pubmed-author:van der KallenCarla J HCJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
122
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
466-72
|
|
pubmed:meshHeading |
pubmed-meshheading:18262228-Adult,
pubmed-meshheading:18262228-Apolipoproteins E,
pubmed-meshheading:18262228-Cardiovascular Diseases,
pubmed-meshheading:18262228-Fatty Liver,
pubmed-meshheading:18262228-Female,
pubmed-meshheading:18262228-Gene Expression Regulation,
pubmed-meshheading:18262228-Genotype,
pubmed-meshheading:18262228-Humans,
pubmed-meshheading:18262228-Hyperlipidemias,
pubmed-meshheading:18262228-Hypertriglyceridemia,
pubmed-meshheading:18262228-Inflammation,
pubmed-meshheading:18262228-Male,
pubmed-meshheading:18262228-Middle Aged,
pubmed-meshheading:18262228-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:18262228-Risk Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E.
|
|
pubmed:affiliation |
Department of Internal Medicine, University Hospital Maastricht, The Netherlands. martijn.brouwers@intmed.unimaas.nl
|
|
pubmed:publicationType |
Journal Article
|
